Krystal Biotech (NASDAQ:KRYS) had its target price upped by Chardan Capital from $57.50 to $75.00 in a research note published on Monday, AnalystRatings.com reports. They currently have a buy rating on the stock.
“We view the receipt of the FDA Therapy (RMAT) designation as a significant positive for the timelines on KB103. This news follows KB103 receiving the EMA Priority Medicines (PRIME) designation on 29 March. As we have noted, Krystal’s market cap is modest relative to companies with PRIME and/or RMAT/BTD designations. We again reiterate: We would not be surprised if Krystal’s market cap crosses $1 billion by 2020E. On today’s news, we update our detailed model, moving the probability of KB103 launch from 55% to 67%, leading to an increase in our 2030E KB103 sales estimate from $492.1 mm to $596.5 mm. With a reduction in our WACC from 12.4% to 11.9%, these changes lead to a 30% KRYS PT target increase, from $57.50 to $75. has demonstrated impressive wound closure data (albeit in small numbers of patients) in the GEM-1 and GEM-2 studies.”,” Chardan Capital’s analyst commented.
Several other research analysts have also commented on the stock. William Blair reiterated a buy rating on shares of Krystal Biotech in a research note on Monday. HC Wainwright reiterated a buy rating and set a $32.00 price objective on shares of Krystal Biotech in a research note on Friday, March 29th. Guggenheim started coverage on shares of Krystal Biotech in a research note on Thursday, May 30th. They set a buy rating and a $31.57 price objective for the company. Cowen reiterated a buy rating on shares of Krystal Biotech in a research note on Monday, May 6th. Finally, ValuEngine upgraded shares of Krystal Biotech from a buy rating to a strong-buy rating in a research note on Friday, March 1st. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $49.83.
Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. Analysts anticipate that Krystal Biotech will post -1.42 EPS for the current year.
Institutional investors have recently modified their holdings of the business. Knott David M acquired a new position in Krystal Biotech during the 4th quarter valued at approximately $31,000. New York State Common Retirement Fund acquired a new position in Krystal Biotech during the 4th quarter valued at approximately $159,000. Citigroup Inc. acquired a new position in Krystal Biotech during the 4th quarter valued at approximately $214,000. BB&T Securities LLC acquired a new position in Krystal Biotech during the 4th quarter valued at approximately $228,000. Finally, TD Asset Management Inc. acquired a new position in Krystal Biotech during the 1st quarter valued at approximately $268,000. Institutional investors and hedge funds own 46.05% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Story: What do investors mean by earnings per share?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.